Junya Iwasaki1,2, Toshiharu Komori1, Fumio Nakagawa1, Hideki Nagase1, Junji Uchida1, Kenichi Matsuo3, Yoshihiro Uto4. 1. Applied Pharmacology Section, Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan. 2. Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan. 3. Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan. 4. Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan uto.yoshihiro@tokushima-u.ac.jp.
Abstract
BACKGROUND/AIM: Trabectedin is a DNA-damaging agent and has been approved for the treatment of patients with advanced soft tissue sarcoma. Schlafen 11 (SLFN11) was identified as a dominant determinant of the response to DNA-damaging agents. The aim of the study was to clarify the association between SLFN11 expression and the antitumor activity of trabectedin. MATERIALS AND METHODS: The antitumor activity of trabectedin was evaluated under different expression levels of SLFN11 regulated by RNA interference and CRISPR-Cas9 systems, and the combined antitumor activity of ataxia telangiectasia and Rad3-related protein kinase (ATR) inhibitor and trabectedin in sarcoma cell lines using in vitro a cell viability assay and in vivo xenograft models. RESULTS: SLFN11-knockdown cell lines had a lower sensitivity to trabectedin, compared to parental cells. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockdown cells and in a SLFN11-knockout xenograft model. CONCLUSION: SLFN11 expression might be a key factor in the antitumor activity of trabectedin. Copyright
BACKGROUND/AIM: Trabectedin is a DNA-damaging agent and has been approved for the treatment of patients with advanced soft tissue sarcoma. Schlafen 11 (SLFN11) was identified as a dominant determinant of the response to DNA-damaging agents. The aim of the study was to clarify the association between SLFN11 expression and the antitumor activity of trabectedin. MATERIALS AND METHODS: The antitumor activity of trabectedin was evaluated under different expression levels of SLFN11 regulated by RNA interference and CRISPR-Cas9 systems, and the combined antitumor activity of ataxia telangiectasia and Rad3-related protein kinase (ATR) inhibitor and trabectedin in sarcoma cell lines using in vitro a cell viability assay and in vivo xenograft models. RESULTS:SLFN11-knockdown cell lines had a lower sensitivity to trabectedin, compared to parental cells. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockdown cells and in a SLFN11-knockout xenograft model. CONCLUSION:SLFN11 expression might be a key factor in the antitumor activity of trabectedin. Copyright
Authors: Ukhyun Jo; Yasuhisa Murai; Sirisha Chakka; Lu Chen; Ken Cheng; Junko Murai; Liton Kumar Saha; Lisa M Miller Jenkins; Yves Pommier Journal: Proc Natl Acad Sci U S A Date: 2021-02-09 Impact factor: 11.205
Authors: Marije E Weidema; Ingrid M E Desar; Melissa H S Hillebrandt-Roeffen; Anke E M van Erp; Mikio Masuzawa; Uta E Flucke; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers Journal: J Cancer Res Clin Oncol Date: 2021-06-03 Impact factor: 4.553
Authors: Sophie E Willis; Claudia Winkler; Martine P Roudier; Tarrion Baird; Paola Marco-Casanova; Emma V Jones; Philip Rowe; Jaime Rodriguez-Canales; Helen K Angell; Felicia S L Ng; Paul M Waring; Darren Hodgson; Jonathan A Ledermann; Johanne I Weberpals; Emma Dean; Elizabeth A Harrington; J Carl Barrett; Andrew J Pierce; Elisabetta Leo; Gemma N Jones Journal: Br J Cancer Date: 2021-10-18 Impact factor: 7.640